Valiant Laboratories Board Approves Up to ₹70 Lakh Investment in Solar Subsidiary AMPYR Renewable;Shares Gain 5%
Power-intensive manufacturers across India have increasingly stopped treating electricity as a fixed overhead and started treating it as something they can actively hedge, by taking a stake in a renewable generator rather than simply signing a supply contract. Group captive open access structures under the Electricity Act let a company buy a small equity slice of a solar or wind project and, in return, draw power from it at a locked-in cost that is largely insulated from the annual tariff hikes utilities pass on to industrial users. That structure sits at the centre of Valiant Laboratories' newest move.
Shares of Valiant Laboratories Ltd . were trading at Rs. 122.75, up 5.00 percent from previous close of Rs. 116.91. The stock opened at Rs. 111.25, reaching an intraday high of Rs. 122.75 and low of Rs. 111.25. The company currently has a market capitalization of Rs. 667 crores.
What's the News?
Valiant Laboratories Limited has announced to the exchanges that the Board of Directors has approved an investment of up to Rs 70 lakh in acquiring shares of its subsidiary, AMPYR Renewable Energy Resources Twelve A Private Limited, which is located in Singapore and is a subsidiary of AMPYR India Asset Holdings Two Pte. Ltd. The investment will be made by way of equity and compulsorily convertible preference shares, in a manner that will bring Valiant Laboratories total ownership of about 1.01% of the equity capital of the target and about 3.60% of its convertible preference shares, as per the ownership requirement in a group captive open access arrangement.
The target entity is running a solar power project as part of a bigger solar park in Mhasale village situated in Dhule district in Maharashtra, and the stake is being acquired to allow Valiant Laboratories to source renewable energy for its manufacturing plant in Tarapur. The company has stated that it is not a related party transaction, does not require any regulatory approval other than the usual corporate consents, and will finish in 12 months or less via definitive agreements, which contain a share purchase agreement and a power delivery agreement.
Financial & Business Analysis
Looking at the quarterly results of Valiant Laboratories Ltd., the company’s consolidated revenue increased by 144.65 percent YoY, from Rs. 47.47 crore in Q1 FY26 to Rs. 116.14 crore in Q1 FY27, and increased by 26.03 percent QoQ from Rs. 92.15 crore in Q4 FY26.
In Q1 FY27 Valiant Laboratories Ltd.’s consolidated net profit increased by 1,059.34 percent YoY, reaching Rs. 21.10 crore compared to Rs. 1.82 crore during the same period last year. As compared to Q4 FY26, the net profit has increased by 1,105.71 percent, from Rs. 1.75 crore.
The basic earnings per share increased by 826.19 percent and stood at Rs. 3.89 as against Rs. 0.42 recorded in the same quarter in the previous year, FY2026.
For an API manufacturer, power is one of the largest and most persistently rising line items in the cost of production, and locking a meaningful share of that consumption into a captive renewable arrangement is one of the few levers a company can pull without touching its core manufacturing footprint. Rather than committing capital to build its own solar capacity, Valiant Laboratories is buying just enough of an existing, operational 50 MW-class project to qualify for captive tariffs, which is a considerably lighter capital commitment than developing a plant from scratch while still delivering the same cost protection.
The move also fits a broader pattern of how the company has been deploying capital recently, adding targeted minority investments, whether in renewable capacity for its existing plant or its speciality chemicals subsidiary on top of its core Paracetamol API business, rather than growing that core business directly. Each of these commitments are small on their own but together they suggest a company working to improve its cost base and diversify its capability set while keeping its core manufacturing operations focused and asset-light on the energy side.
Industry Overview
This comes at a time when the power source shift is taking place in Indian industries. India's total OMC solar power capacity has reached around 36 GW by June 2026, representing nearly 20 GW of new capacity in just the first half of the year – a 42% increase from the previous half year, with manufacturing units and other large electricity consumers contributing to this expansion. In higher tariff industrial states, group captive structures in particular have emerged as the preferred option due to the fact that they generally receive a cross-subsidy exemption on the surcharges to cross-subsidy grid power.
That's an economic shift for any power-hungry manufacturer. The captive power generation market in India was worth approximately Rs 1.18 lakh crore in 2024, and is expected to continue to increase at approximately 8.55% compound annual growth rate (CAGR) until 2030. Typically, industrial users can realize annual reductions of 30% to 40% in their effective electricity cost with the use of compliant captive and group captive configurations. That much potential saving is what is making that little equity cheque into a long-term cost benefit for a plant such as Valiant Laboratories' Tarapur works.
Company Overview
Valiant Laboratories Limited is a pharmaceutical ingredient manufacturer focused on producing Paracetamol API and bulk drugs across multiple pharmacopeia grades, operating a manufacturing facility in the Tarapur Industrial Area of Palghar, Maharashtra, supported by an in-house R&D unit for quality testing and process development. Its wholly owned subsidiary, Valiant Advanced Sciences Private Limited, is separately building out the group's presence in specialty chemicals and related derivatives.